Press Release: Viela Bio : Viela Bio Announces Additional Positive Results with UPLIZNA (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion-
Read full article »
Viela Bio is a Maryland-based biotechnology company that develops and commercializes therapeutics for autoimmune and severe inflammatory diseases.
Read more